Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
24 hedge funds and large institutions have $1.47M invested in Vyant Bio, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 8 closing their positions.
149% more capital invested
Capital invested by funds: $592K → $1.47M (+$880K)
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
11% less funds holding
Funds holding: 27 → 24 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$745K |
| 2 |
Renaissance Technologies
New York
|
+$301K |
| 3 |
VF
Virtu Financial
New York
|
+$55.1K |
| 4 |
FPB
First PREMIER Bank
Sioux Falls,
South Dakota
|
+$10.1K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$9.33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$66K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$9K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6K |
VYNT Hedge Fund Activity: Q1 2019 in Review
24 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q1 2019, worth a combined $1.47M — up 149% from $592K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VYNT and 5 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Perkins Capital Management, adding an estimated $745K. The largest seller was Granahan Investment Management, exiting entirely with an estimated $66K sold.
- 24 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q1 2019, down from 27 in Q4 2018.
- Funds reported $1.47M of Vyant Bio, Inc. Common Stock stock for Q1 2019, up 149% quarter-over-quarter.
- 5 funds opened new Vyant Bio, Inc. Common Stock positions in Q1 2019 and 8 closed out, a net change of -3 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q1 2019 was Perkins Capital Management, an estimated $745K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q1 2019 was Granahan Investment Management, an estimated $66K sold.
Based on aggregated 13F filings for Q1 2019.